Learn about the four phases of a clinical trial. Each phase helps move the study along, step by step. The purpose of a clinical trial could be to study a medicine, a therapy, or a method of preventing or detecting a disease. Donate Now. Give Monthly Give In Honor.
Clinical trials. Diversity in clinical trials: Why it matters. Diversity in clinical trials Clinical trials for kidney disease should include participants who represent the people who have kidney disease all around the world. Myths and facts about clinical trials - Take the quiz! Take a quick quiz to learn about the myths and facts about clinical trials Download the clinical trials myths and facts sheet. How do clinical trials work?
Advantages and disadvantages of participating Learn about the advantages and disadvantages of participating in clinical trials. Who pays for my healthcare during a trial? Exclusion criteria and reported clinical characteristics of subjects were abstracted. Rates of exclusion and reporting of baseline characteristics of study participants were compared for CKD, diabetes, history of smoking, and hypertension.
Eighty-six trials randomizing patients were identified. Hence, there is urgent need for novel therapies to slow the progression of DKD and optimize the health of this patient population. The purpose of this study is to examine the effect of a supplement on mesenchymal stem cells, physical body function or frailty , kidney function, and total clearance of senescent cells in individuals with CKD.
At present, we are enrolling participants with CKD, with a subset This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attaches.
These therapies have never been compared at appropriate doses. Further, they will be study in patients with kidney disease for the first time. The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease CKD to evaluate the safety and efficacy of daprodustat.
The purpose of this multi-center event-driven study in non-dialysis ND participants with anemia associated with chronic kidney disease CKD is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa. The primary purpose of this study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease.
To compare the effect of senolytic drugs on cellular senescence, physical ability or frailty, and adipose tissue-derived MSC functionality in patients with chronic kidney disease. Primary Objectives: To assess the efficacy of a single 3-day treatment regimen with dasatinib and quercetin senolytic drugs on clearing senescent adipose-derived MSC in patients with CKD.
To assess the efficacy of a single 3-day treatment regimen with dasatinib and quercetin senolytic drugs on improving adipose-derived MSC functionality in patients with CKD. Secondary Objective: To assess the short-term effect of a single 3-day treatment regimen with dasatinib and quercetin senolytic drugs on This study aims to determine the potential barriers that contribute to fewer patients with Chronic Kidney Disease CKD being placed on the waiting list for a kidney transplant and that accomplished through evaluating:.
The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease. To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects with preclinical systolic dysfunction PSD and renal kidney dysfunction.
The purpose of this study is to investigate the central hypothesis that autologous, adipose-derived MSC preconditioned by hypoxia will have superior kidney angiogenic function compared to untreated MSC from humans with HN and CKD. The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney Disease subjects with chronic kidney disease in stages CKD1, CKD2 or CKD3.
The purpose of this study is to define the effects of decreasing the furosemide lasix dose on heart, kidney and biochemical balance, in people with compensated heart failure and kidney dysfunction and also in people with compensated heart failure without kidney dysfunction.
Participants will be assigned at random to a routine invasive strategy INV with cardiac catheterization cath followed by revascularization plus optimal medical therapy OMT or to a conservative strategy CON of OMT, with cath and
0コメント